Bone marrow-derived CD34+ cells are a well-characterized population of stem cells that
have traditionally been used clinically to reconstitute the hematopoietic system after …

CD34+ cells are haematopoietic stem cells used therapeutically in patients undergoing
radiation or chemotherapy due to their regenerative potential and ability to restore the …

Cell therapy has received significant attention as a novel therapeutic approach to restore
cardiac function after injury. CD34-positive (CD34+) stem cells have been investigated for …

An increasing number of patients have refractory angina despite optimal medical therapy
and are without further revascularization options. Preclinical studies indicate that human …

Background/Objectives: A large number of patients with coronary artery disease experience
angina that is not suitable for revascularization and is refractory to conventional medical …

Background—A growing population of patients with coronary artery disease experiences
angina that is not amenable to revascularization and is refractory to medical therapy …

Preclinical trials indicate that CD34+ cells represent an effective angiogenic stem cell
component. Early-phase clinical trials suggest that intramyocardial administration of …

Background: Cell therapy for cardiovascular disease has been limited by low engraftment of
administered cells and modest therapeutic effects. Bone marrow (BM)-derived CD31+ cells …

Rationale: Bone marrow (BM) cells play an important role in physiological and therapeutic
neovascularization. However, it remains unclear whether any specific uncultured BM cell …

CD34 is a cell surface antigen expressed in numerous stem/progenitor cells including
hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which are known …